ArticleFrontiers in immunology2025
Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adherence to disease-modifying therapies (DMTs) in multiple sclerosis (MS) is crucial for effective treatment. Understanding the patients' perspective and identification of factors influencing adherence to treatment may allow improved disease management. Objective: This study attempted to evaluate adherence to DMTs in people with MS and explore potential patient-related factors influencing level of adherence. Methods: 121 patients with relapsing-remitting MS (90% women, aged 34.0 ± 10 years participated in the online self-reported survey, which included: Adherence in Chronic Diseases scale (ACDS), Patient health questionnaire (PHQ-9) as a measure of depression, Modified Fatigue Impact Scale (MFSI), Perceived Stress Scale (PSS-10), Acceptance of Illness Scale (AIS), and a questionnaire about demographics and basic patient-reported clinical data. Results: The ACDS results comprised between 9 and 28 points, with a mean value of 24.0 ± 3.8, indicating a moderate level of adherence. Fatigue was reported by 70% of patients and the results of MFIS showed significant correlation with ACDS (R=-0.260; p=0.004) and AIS score (R=0.487; p <0.001). Relationships were found between the results of AIS and PHQ-9 and PSS-10 but none of them was associated with ACDS, and neither were demographic data. Conclusions: The adherence to treatment among MS patients is moderate and significantly associated with fatigue. Evaluating the level of adherence and the patients' psychosocial condition may contribute to personalized and optimal therapeutic approach.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.